Exposure to bisphosphonates and risk of colorectal cancer: A population-based nested case-control study

Cancer

Volumn 118, Issue 5, 2012, Pages 1236-1243

  Singh, Harminder ^a   Nugent, Zoann ^a,b   Demers, Alain ^a,b   Mahmud, Salaheddin ^a,b   Bernstein, Charles ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b CANCERCARE MANITOBA   (Canada)

Author keywords

bisphosphonates; chemoprevention; colorectal cancer; epidemiology

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANADA; CANCER INCIDENCE; CANCER REGISTRY; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; GASTROINTESTINAL ENDOSCOPY; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; SEX DIFFERENCE; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; CARCINOMA; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; COMORBIDITY; DIPHOSPHONATES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OCCUPATIONAL EXPOSURE; POPULATION; REGISTRIES; RISK FACTORS;

EID: 83255191619     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26395     Document Type: Article

References (36)

1. Canadian Cancer Society/National Cancer Institute of Canada. Canadian Cancer Statistics 2009. Toronto, Ontario, Canada: Canadian Cancer Society/National Cancer Institute of Canada; 2009.
2. Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 2008; 100: 1672-1694.
3. Post DM, Katz ML, Tatum C, Dickinson SL, Lemeshow S, Paskett ED,. Determinants of colorectal cancer screening in primary care. J Cancer Educ. 2008; 23: 241-247.
4. Arber N, Levin B,. Chemoprevention of colorectal neoplasia: the potential for personalized medicine. Gastroenterology. 2008; 134: 1224-1237. (Pubitemid 351451998)
5. Holder KK, Kerley SS,. Alendronate for fracture prevention in postmenopause. Am Fam Physician. 2008; 78: 579-581.
6. Heras P, Karagiannis S, Kritikos K, Hatzopoulos A, Mitsibounas D,. Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer. Eur J Cancer Care (Engl). 2007; 16: 539-542.
7. Santini D, Vespasiani GU, Vincenzi B, et al. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol. 2003; 14: 1468-1476. (Pubitemid 37304600)
8. Santini D, Virzi V, Fratto ME, et al. Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting. Curr Cancer Drug Targets. 2010; 10: 46-54.
9. Sewing L, Steinberg F, Schmidt H, Goke R,. The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis. Apoptosis. 2008; 13: 782-789.
10. Todaro M, D'Asaro M, Caccamo N, et al. Efficient killing of human colon cancer stem cells by gamma-delta T lymphocytes. J Immunol. 2009; 182: 7287-7296.
11. Sassa S, Okabe H, Nemoto N, Kikuchi H, Kudo H, Sakamoto S,. Ibadronate may prevent colorectal carcinogenesis in mice with ulcerative colitis. Anticancer Res. 2009; 29: 4615-4619.
12. Hotes Ellison J, Wu XC, McLaughlin C, et al. eds. Cancer in North America, 1999-2003. Volume 1: Incidence. Springfield, IL: North American Association of Central Cancer Registries Inc.; 2006.
13. Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A,. Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol. 1999; 149: 916-924. (Pubitemid 29230706)
14. Blanchard JF, Ludwig S, Wajda A, et al. Incidence and prevalence of diabetes in Manitoba, 1986-1991. Diabetes Care. 1996; 19: 807-811. (Pubitemid 26286983)
15. Lix L, Yogendran M, Burchill C, et al. Defining and Validating Chronic Diseases: An Administrative Data Approach. Winnipeg, Manitoba, Canada: Manitoba Centre for Health Policy; 2006.
16. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005; 43: 1130-1139. (Pubitemid 41587600)
17. Sundararajan V, Quan H, Halfon P, et al. Cross-national comparative performance of 3 versions of the ICD-10 Charlson index. Med Care. 2007; 45: 1210-1215.
18. Pomerleau J, Pederson LL, Ostbye T, Speechley M, Speechley KN,. Health behaviours and socio-economic status in Ontario, Canada. Eur J Epidemiol. 1997; 13: 613-622. (Pubitemid 27375064)
19. Chuang YC, Cubbin C, Ahn D, Winkleby MA,. Effects of neighbourhood socioeconomic status and convenience store concentration on individual level smoking. J Epidemiol Commun Health. 2005; 59: 568-573. (Pubitemid 40904783)
20. Whitlock G, MacMahon S, Vander HS, Davis P, Jackson R, Norton R,. Association of environmental tobacco smoke exposure with socioeconomic status in a population of 7725 New Zealanders. Tob Control. 1998; 7: 276-280. (Pubitemid 128656170)
21. Siegel RL, Jemal A, Thun MJ, Hao Y, Ward EM,. Trends in the incidence of colorectal cancer in relation to county-level poverty among blacks and whites. J Natl Med Assoc. 2008; 100: 1441-1444.
22. Martens PJ, Frohlich N, Carriere KC, Derksen S, Brownell M,. Embedding child health within a framework of regional health: population health status and sociodemographic indicators. Can J Public Health. 2002; 93 (suppl 2): S15-S20. (Pubitemid 36157488)
23. Martens PJ, Derksen S, Gupta S,. Predictors of hospital readmission of Manitoba newborns within 6 weeks postbirth discharge: a population-based study. Pediatrics. 2004; 114: 708-713. (Pubitemid 41529528)
24. Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V,. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort [serial online]. BMJ. 2010; 341: c4444.
25. Rennert G, Pinchev M, Rennert HS, Gruber SB,. Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol. 2011; 29: 1146-1150.
26. Russell RG, Xia Z, Dunford JE, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci. 2007; 1117: 209-257. (Pubitemid 350191297)
27. Winter MC, Holen I, Coleman RE,. Exploring the antitumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev. 2008; 34: 453-475.
28. Neville-Webbe HL, Gnant M, Coleman RE,. Potential anticancer properties of bisphosphonates. Semin Oncol. 2010; 37 (suppl 1): S53-S65.
29. Abrahamsen B,. Bisphosphonate adverse effects, lessons from large databases. Curr Opin Rheumatol. 2010; 22: 404-409.
30. Watts NB, Diab DL,. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010; 95: 1555-1565.
31. Cardwell CR, Abnet CC, Cantwell MM, Murray LJ,. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA. 2010; 304: 657-663.
32. Lewis JD, Capra AM, Achacoso NS, et al. Medical therapy for diabetes is associated with increased use of lower endoscopy. Pharmacoepidemiol Drug Saf. 2007; 16: 1195-1202. (Pubitemid 350120644)
33. Yang YX, Hennessy S, Propert K, Hwang WT, Sarkar M, Lewis JD,. Chronic statin therapy and the risk of colorectal cancer. Pharmacoepidemiol Drug Saf. 2008; 17: 869-876.
34. Rahme E, Pettitt D, Lelorier J,. Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal anti-inflammatory drugs in an elderly population. Arthritis Rheum. 2002; 46: 3046-3054. (Pubitemid 35315900)
35. Weinstein SJ, Yu K, Horst RL, Ashby J, Virtamo J, Albanes D,. Serum 25-hydroxyvitamin D and risks of colon and rectal cancer in Finnish men. Am J Epidemiol. 2011; 173: 499-508.
36. Kavanaugh CJ, Trumbo PR, Ellwood KC,. Qualified health claims for calcium and colorectal, breast, and prostate cancers: the US Food and Drug Administration's evidence-based review. Nutr Cancer. 2009; 61: 157-164.